Skip to main content
. Author manuscript; available in PMC: 2015 Oct 15.
Published in final edited form as: Int J Cancer. 2014 Mar 20;135(8):1931–1939. doi: 10.1002/ijc.28838

Figure 2.

Figure 2

Incremental net monetary benefit (INMB) of A) targeting follow-up, B) targeting under-screeners, C) targeting non-screeners and D) perfect compliance. Point estimate (solid line) and credible bounds (dotted lines) for the INMB assuming perfect compliance compared to status quo participation using cytology and are shown as a function of the willingness to pay (WTP) threshold (λ) per year of life saved (YLS). Credible bounds reflect uncertainty in input values across the good-fitting parameter sets.